01—Abstract
Summary
Summary of the 8-K filed August 29, 2025. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. filed a Form 8-K on August 29, 2025 reporting two executive leadership changes under Item 5.02.
On August 29, 2025, the Board of Directors appointed Dana T. Aftab, Ph.D., the Company's current Executive Vice President, Discovery and Translational Research and Chief Scientific Officer, as Executive Vice President, Research and Development. Information about Dr. Aftab's background, compensatory arrangements, and related party transactions is incorporated by reference from the Company's definitive proxy statement on Schedule 14A filed April 16, 2025.
Also effective August 29, 2025, Amy C. Peterson, M.D., concluded her service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer. In connection with her departure, Dr. Peterson is entitled to payments under the Company's Change in Control and Severance Benefit Plan, as amended and restated, and applicable law.
The filing does not state the amount of those payments. For investors, the filing signals a reshuffling of the senior research and medical leadership team, with the research chief taking an expanded R&D role and the chief medical officer position being vacated. The filing does not describe the reasons for the departure or any succession plan for the Chief Medical Officer role.
02—Key points
Key Highlights
- Dana T. Aftab, Ph.D., appointed Executive Vice President, Research and Development, effective August 29, 2025, while remaining the Company's Chief Scientific Officer role as described.
- Dr. Aftab's prior title was Executive Vice President, Discovery and Translational Research and Chief Scientific Officer.
- Amy C. Peterson, M.D., concluded service as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer effective August 29, 2025.
- Dr. Peterson is entitled to severance-related payments under the Company's Change in Control and Severance Benefit Plan, as amended and restated, and applicable law.
- Compensation and background details for Dr. Aftab are incorporated by reference from the April 16, 2025 proxy statement (Schedule 14A).
- The filing does not disclose the amount of payments to Dr. Peterson or any successor for the Chief Medical Officer role.
03—Questions
Frequently Asked Questions
Who is taking over the research and development leadership at Exelixis?
Dana T. Aftab, Ph.D., the Company's existing Executive Vice President, Discovery and Translational Research and Chief Scientific Officer, was appointed Executive Vice President, Research and Development by the Board of Directors on August 29, 2025.
Why did Amy C. Peterson leave Exelixis?
The filing states that Dr. Peterson concluded her service effective August 29, 2025, but does not give a reason for her departure.
What payments will the departing Chief Medical Officer receive?
The filing states that Dr. Peterson is entitled to payments in accordance with the Company's Change in Control and Severance Benefit Plan, as amended and restated, and applicable law. It does not specify amounts.
Where can investors find more about Dr. Aftab's compensation and background?
The filing incorporates by reference this information, including any compensatory arrangements and related party transactions, from the Company's definitive proxy statement on Schedule 14A filed with the SEC on April 16, 2025.
Does this filing name a new Chief Medical Officer?
No. The filing does not name a successor to Dr. Peterson's position as Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer.
04—Continue